Constrained Compounds as CGRP-Receptor Antagonists
AssigneeBristol-Myers Squibb Company
InventorsPrasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang
Life of this patent
Estimating the term…
Abstract
The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Claims14
A compound of Formula I
- wherein:
- R1 is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C5-7cycloalkenyl, C1-6(C3-7cycloalkyl)alkyl, C1-6haloalkyl, C1-6(C1-6alkoxy)alkyl, C1-6(Ar1)alkyl, C1-6(NR7R8)alkyl, N—(R9)-pyrrolidinyl or N—(R9)-piperidinyl;
- R2 is hydrogen, halo, hydroxy, C1-6alkyl, C2-6alkenyl, benzyloxy, or NR7R8;
- R3 is hydrogen, hydroxy, halo, C1-6alkyl, or C2-6alkenyl;
- or R2 and R3 taken together are CHNNR5;
- R4 is hydrogen, halo or C1-6alkyl, or C2-6alkenyl;
- R5 is hydrogen or C1-6alkyl;
- R6 is hydrogen, C1-6alkyl,
- or NR5R6 taken together is
- R7 is hydrogen or C1-6alkyl;
- R8 is hydrogen or C1-6alkyl;
- or
- NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N—(R9)-piperazinyl, morpholinyl, and thiomorpholinyl;
- R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkoxycarbonyl;
- R10 is phenyl, naphthyl, pyridinyl, pyridinyl N-oxide, quinolinyl, quinolinyl N-oxide, isoquinolinyl, or isoquinolinyl N-oxide, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy, and phenyl;
- or R10 is selected from the group consisting of
- each R11 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, or C1-6alkoxy;
- Ar1 is phenyl, naphthyl, pyridinyl, or imidazolyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
- Ar2 is phenyl, naphthyl, or pyridinyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
- X—Y is aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl;
- Z is N or CH;
- and
- n is 0 or 1;
- or a pharmaceutically acceptable salt or solvate thereof.
A compound of Formula II
- where
- R1 is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C5-7cycloalkenyl, C1-6(C3-7cycloalkyl)alkyl, C1-6haloalkyl, C1-6(C1-6alkoxy)alkyl, C1-6(Ar1)alkyl, C1-6(NR7R8)alkyl, N—(R9)-pyrrolidinyl or N—(R9)-piperidinyl;
- R4 is hydrogen, halo or C1-6alkyl, or C2-6alkenyl;
- R5 is hydrogen or C1-6alkyl;
- R6 is hydrogen, C1-6alkyl,
- or NR5R6 taken together is
- R7 is hydrogen or C1-6alkyl;
- R8 is hydrogen or C1-6alkyl;
- or
- NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N—(R9)-piperazinyl, morpholinyl, and thiomorpholinyl;
- R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkoxycarbonyl;
- R10 is phenyl, naphthyl, pyridinyl, pyridinyl N-oxide, quinolinyl, quinolinyl N-oxide, isoquinolinyl, or isoquinolinyl N-oxide, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy, and phenyl;
- or R10 is selected from the group consisting of
- each R11 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, or C1-6alkoxy;
- Ar1 is phenyl, naphthyl, pyridinyl, or imidazolyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
- Ar2 is phenyl, naphthyl, or pyridinyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
- X—Y is aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl;
- Z is N or CH;
- and
- the carbon bearing the asterisk is either the (S) configuration or the (R) configuration;
- or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.